NCT05176639 (THRIVE) is a Phase 3 clinical trial of VRDN-001 Phase 3 Cohort (THRIVE) in Thyroid Eye Disease, sponsored by Viridian Therapeutics, Inc..

Who is sponsoring NCT05176639?

NCT05176639 is sponsored by Viridian Therapeutics, Inc..

What drugs are being tested in NCT05176639?

Interventions in NCT05176639: VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo.

What condition does NCT05176639 study?

NCT05176639 studies Thyroid Eye Disease.

Is NCT05176639 still recruiting?

NCT05176639 is currently completed. Last updated 18 July 2025.

Last reviewed 2025-07-18 · How we verify

NCT05176639: THRIVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )

Completed Phase 3 Last updated 18 July 2025

What this trial tests

Phase 3 trial testing VRDN-001 Phase 3 Cohort (THRIVE) in Thyroid Eye Disease in 113 participants. Completed in 27 March 2025.

Timeline

3 December 2021

Primary endpoint
15 July 2024

27 March 2025

Quick facts

Lead sponsor	Viridian Therapeutics, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	113
Start date	3 December 2021
Primary completion	15 July 2024
Estimated completion	27 March 2025
Sites	53 locations across France, United Kingdom, Germany, Poland, Australia, United States, Spain

Drugs / interventions tested

VRDN-001 Phase 3 Cohort (THRIVE) — full drug profile →
VRDN-001 Placebo — full drug profile →

Conditions studied

Thyroid Eye Disease — all drugs for Thyroid Eye Disease →

Sponsor

Viridian Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Thyroid Eye Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objective of this clinical trial is to establish the safety, tolerability, and efficacy of veligrotug, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of veligrotug in active TED patients who received 10 mg/kg.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Liu ZL, Chen HH, Zheng LL, Sun LP, et al · · 2023 · cited 808× · PMID 37169756 · DOI 10.1038/s41392-023-01460-1
From geroscience to precision geromedicine: Understanding and managing aging.
Kroemer G, Maier AB, Cuervo AM, Gladyshev VN, et al · · 2025 · cited 139× · PMID 40250404 · DOI 10.1016/j.cell.2025.03.011
Antibodies to watch in 2025.
Crescioli S, Kaplon H, Wang L, Visweswaraiah J, et al · · 2025 · cited 87× · PMID 39711140 · DOI 10.1080/19420862.2024.2443538
The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Moledina M, Damato EM, Lee V. · · 2024 · cited 37× · PMID 38374366 · DOI 10.1038/s41433-024-02967-9
Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
Smith TJ. · · 2022 · cited 34× · PMID 36346686 · DOI 10.1210/clinem/dgac328
Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice.
Yang S, Fang Y, Ma Y, Wang F, et al · · 2025 · cited 22× · PMID 40268524 · DOI 10.1002/ctm2.70313
A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.
Kulbay M, Tanya SM, Tuli N, Dahoud J, et al · · 2024 · cited 18× · PMID 39519180 · DOI 10.3390/ijms252111628
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.
Gjølberg TT, Mester S, Calamera G, Telstad JS, et al · · 2025 · cited 10× · PMID 40156757 · DOI 10.1007/s40259-025-00708-2

Verify or expand the search:

Other recruiting trials for Thyroid Eye Disease

Currently open trials in the same condition.

NCT07423013 — Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. · NA · recruiting
NCT07113262 — A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease · Phase 3 · recruiting
NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting
NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
NCT06625398 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) · Phase 3 · active not recruiting

Other Viridian Therapeutics, Inc. trials

Trials by the same sponsor.

NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
NCT06625398 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
NCT06384547 — A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) · Phase 3 · completed
NCT06179875 — An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 · Phase 3 · completed
NCT06021054 — An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease ( · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05176639 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Viridian Therapeutics, Inc.
Last refreshed: 18 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing